Videos
The study evaluates Daratumumab (DARA) in delaying progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM). It investigates DARA's efficacy as monotherapy compared to active monitoring in delaying disease progression and its impact on progression-free survival (…
Videos
What Is the Prognosis for Multiple Myeloma? | Myeloma in a Minute or Less
What is the prognosis for someone with multiple myeloma? Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, explains how survival rates have improved dramatically.
…
Videos
ELRA, a BCMA/CD3 bispecific antibody, was evaluated in the MM-9 phase 1/2 trial for patients with relapsed/refractory multiple myeloma (RRMM). The study explored different dosing regimens and observed comparable efficacy to previous studies, with manageable safety profiles but varying rates of…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the February 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
This study investigates the efficacy and safety of lisaftoclax, a novel BCL-2 inhibitor, in combination with pomalidomide and dexamethasone (Pd) or daratumumab, lenalidomide, and dexamethasone (DRd) in patients with relapsed/refractory multiple myeloma (R/R MM) and lisaftoclax with Pd in R/R AL…
Videos
The study DREAMM-9 evaluates belantamab mafodotin (belamaf) in combination with VRd for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant (ASCT). It explores various dosing schedules and reports favorable safety profiles with notable ocular events. The study…
Videos
Q&A | Hope for High-Risk Multiple Myeloma: Latest Treatments & Life Expectancy Insights
Join Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, as he answers pressing questions from the high-risk multiple myeloma support group.…
Videos
Patient-Centric Myeloma Research at ASH 2024: Quality of Life, Exercise, Nutrition & More
IMF Chief Medical Officer Dr. Joseph Mikhael dives into patient-centric research from #ASH24, focusing on quality of life for multiple myeloma patients.
Discover groundbreaking studies on exercise,…
Videos
Myeloma Research: Late Relapse, CAR T-Cell Therapy & Bispecific Antibodies at ASH 2024
International Myeloma Foundation's Chief Medical Officer Dr. Joseph Mikhael shares the latest breakthroughs in multiple myeloma research from the ASH Annual Meeting. Learn about promising therapies for…
Videos
Belantamab & CAR T-Cell Therapy: Key ASH 2024 Updates on Early Myeloma Relapse
IMF Chief Medical Officer Dr. Joseph Mikhael breaks down major findings on early relapse from the 2024 American Society of Hematology (ASH).
IMF Chief Medical Officer Dr. Joseph…
Videos
Frontline Therapy Advances for Multiple Myeloma Patients | ASH 2024 Insights for Patients
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the latest research on frontline therapy for multiple myeloma presented at ASH 2024.
Learn about…
Videos
This study explores the implications of measurable residual disease progression (MRD-P) in patients with newly diagnosed multiple myeloma (NDMM) treated with quadruplet therapy (QUAD) and autologous stem cell transplantation (ASCT). The research highlights how MRD-P, defined as a quantitative…
Videos
This study explores ISB 2001, a novel trispecific antibody designed to target BCMA and CD38 on myeloma cells using Ichnos’ BEAT® technology. The Phase 1 trial aims to assess safety, tolerability, pharmacokinetics, and efficacy in heavily pre-treated relapsed/refractory multiple myeloma (RRMM)…
Videos
The study investigates the efficacy and safety of MEZId, an oral CELMoD™ agent, in combination with novel therapeutic agents (TAZ, BMS-986158, TRAM) in patients with relapsed/refractory multiple myeloma (RRMM). The CA057-003 trial (NCT05372354) explores triplet combinations targeting dysregulated…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the January 2025 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Page
Harnessing the Power of Data for the Future of the International Myeloma Foundation
Imagine being served up content that met you where you are in your patient journey. You visit the IMF website (myeloma.org) and learn what clinical trials you qualify for, or which myeloma experts can best help…
Videos
New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024
IMF Chief Medical Officer Dr. Joseph Mikhael takes a deeper dive into the groundbreaking research presented at the American Society of Hematology (ASH) annual meeting, highlighting the AQUILA…
Audio
A Day in the Life of Donna Kidder | Multiple Myeloma Inspiration
In this episode of A Day in the Life Podcast, brought to you by the International Myeloma Foundation, myeloma patient Donna Kidder shares how she lives her life with the disease.
Donna Kidder…
Videos
This abstract discusses the efficacy and safety outcomes from the Phase 1b/2 STOMP trial evaluating selinexor in combination with pomalidomide and dexamethasone (SPd) for relapsed/refractory multiple myeloma (RRMM). Results show promising overall response rates (ORR), particularly in the SPd60…
Videos
In newly diagnosed multiple myeloma patients eligible for transplant, combining isatuximab with lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly increased minimal residual disease negativity compared to RVd alone. This phase III trial, GMMG-HD7, demonstrated that Isa-RVd…
Videos
The advent of bispecific antibodies like teclistamab and elranatamab has revolutionized the management of relapsed and refractory multiple myeloma (RRMM). This study from the University of Miami explores the efficacy of prophylactic tocilizumab in mitigating cytokine release syndrome (CRS)…
Videos
This study investigates the effects of a high fiber plant-based dietary (HFPBD) intervention on patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). The pilot trial included 20 participants with BMI ≥ 25, focusing on feasibility, metabolic…
Videos
Cevostamab, a FcRH5xCD3 bispecific antibody, shows promising results in heavily treated patients with relapsed/refractory multiple myeloma (RRMM). In a Phase I study, it demonstrated dose-dependent efficacy and manageable safety profiles, particularly at the 160mg target dose level administered…
Videos
This study explores the impact of omitting 24-hour urine assessments from International Myeloma Working Group (IMWG) response criteria in multiple myeloma (MM), focusing on its effect on treatment response and prognostication. Secondary analysis of Phase 3 trial data (BMT CTN 0702) indicates…
Page
From August 29, 2024, to September 3, 2024, the International Myeloma Foundation embarked on its Inaugural Iceland Cycling Expedition. We are tremendously grateful to the 11 fundraisers who fearlessly tackled the arduous terrain of Iceland to raise funds to find a cure for multiple…
Videos
The DREAMM-7 study (NCT04246047) compared the efficacy and safety of belantamab mafodotin (BVd) versus daratumumab (DVd) in relapsed/refractory multiple myeloma (MM) patients who had received at least one prior line of therapy. BVd demonstrated superior progression-free survival (PFS) with a median…
News Article
Dear Members of the Myeloma Community,
As firefighters continue to bravely battle the wildfires across Southern California, myeloma patients and many of…
Videos
DOWNLOAD SLIDES
Videos
How Can You Safely Exercise While Living with Multiple Myeloma?Join Dr. Joseph Mikhael, Medical Advisor to the International Myeloma Foundation, as he explains the importance of staying active, the safest types of exercises, and what to avoid.Exercise is essential for healthy living, even with a…
News Article
IMF Presents Top Ten Oral and Poster Abstracts at the 2024 ASH Annual Meeting
Oral and poster abstracts co-authored by IMF President & CEO and 29-year myeloma patient Yelak Biru, IMF Chief Medical Officer Dr. Joseph Mikhael, and members of the IMF Scientific Advisory Board (SAB).…
Videos
Watch the Replay: Discover the Latest Myeloma Research at ASH — Insights for Patients & Families
In case you missed it, IMF Chief Medical Officer Dr. Joseph Mikhael and our support group leaders went live on Facebook on the evening of Monday, December 9, to discuss the key myeloma…
Videos
How Long Do I Have to Live with Myeloma? In a Minute or Less
Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, answers this common question in a minute or less: How long do I have to live with myeloma?
For more guidance or if…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the December 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Page
The International Myeloma Working GroupTM (IMWG) stands as a premier global collaborative of myeloma specialists, bringing together 345 leading researchers and clinicians from 43 countries. This extraordinary panel represents the forefront of multiple myeloma research, treatment, and innovation…
University of North Texas Reports on IMF President and CEO, and Myeloma Patient Yelak Biru's Journey
News Article
Yelak Biru: Inspiring Hope and Advocacy as IMF President and Myeloma Survivor
Diagnosed with multiple myeloma at just 25, Yelak Biru ('95, '97 M.S.) defied the odds and built an extraordinary life of resilience and impact. Now celebrating nearly 30 years as a myeloma survivor, he is the…
News Article
Time-Sensitive Information for People with Medicare Who Take Revlimid
People across the U.S. are experiencing significant difficulty finding Medicare Part D plans that include Revlimid on their 2025 formularies. The formulary is the list of drugs that are covered by a plan.
This…
News Article
IMF Medical Student Scholar for Health Equity in Myeloma Semegne Hiruy Receives Prestigious 2024 ASH Abstract Achievement Award
Poster Abstracts 3769, 3771, 3776, and 3783 to be presented on December 8 at the San Diego Convention Center.
STUDIO CITY, CA, December 5,…
Videos
How to Find a Hematologist Oncologist in a Minute or Less
Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, explains how the IMF can help. Visit www.myeloma.org, email [email protected], or call the IMF InfoLine at 1-818-487-7455 to find a…
IMF Person
Dr. Sagar Lonial is Professor and Chair of the Department of Hematology and Medical Oncology at the Emory University School of Medicine. He is the Chief Medical Officer of the Winship Cancer Institute at Emory University and is internationally recognized as a leading authority in multiple myeloma…
IMF Person
Dr. Nikhil Munshi is a world-renowned leader in translational research for multiple myeloma. He is a Professor of Medicine at Harvard Medical School, holding the Kraft Family Chair, and serves as Director of Basic and Correlative Science and Associate Director of the Jerome Lipper Multiple Myeloma…
IMF Person
As Managing Partner at ZS Associates, Maria Whitman oversees global commercialization strategy and solutions, driving transformation across industries. She played a key role in creating Myelo, the IMF’s AI-powered chatbot for patients, care partners, and healthcare professionals. With nearly 25…
IMF Person
Kent Oliver, Director of Strategic Growth at Raanes & Oliver Capital Advisors, is a dedicated advocate, philanthropist, and myeloma survivor. Diagnosed with multiple myeloma at just 34 in 2015, he has devoted his life to supporting the myeloma community. His initiatives include developing Myelo…
News Article
The International Myeloma Foundation Welcomes Four Newly Elected Members to the IMF Board of Directors
Extends Gratitude to Outgoing Board Members for Their Years of Dedicated Service to the IMF Board
STUDIO CITY, Calif., Nov. 26, 2024 — The International…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the November 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…